摘要
目的研究分析SOX化疗方案治疗Ⅱ~Ⅲ期胃癌的临床效果。方法简单随机选取2020年1月—2022年12月在徐州医科大学附属医院行手术治疗的Ⅱ~Ⅲ期胃癌患者60例,将患者依据随机数表法进行分组,组别为参照组(n=30)与观察组(n=30)。参照组术后应用CAPEOX化疗方案,观察组术后应用SOX化疗方案,对两组临床疗效、血清肿瘤标志物水平、不良反应发生情况予以统计比较。结果与参照组相比,观察组临床总有效率(93.33%)更高,差异有统计学意义(χ^(2)=4.320,P<0.05)。治疗前,两组糖类癌抗原199(carbohy⁃drate cancer antigen199,CA199)、糖类癌抗原242(carbohydrate cancer antigen242,CA242)、糖类癌抗原724(car⁃bohydrate cancer antigen724,CA724)、癌胚抗原(carcinoembryonic antigen,CEA)水平对比,差异无统计学意义(P>0.05);治疗后,观察组CA199、CA242、CA724、CEA水平低于参照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论SOX化疗方案治疗Ⅱ~Ⅲ期胃癌的临床效果更确切,能够进一步降低血清肿瘤标志物水平,且不会明显增加不良反应。
Objective To study and analyze the clinical effect of SOX chemotherapy regimen in the treatment of stageⅡ-Ⅲgastric cancer.Methods 60 patients with stageⅡ-Ⅲgastric cancer who underwent surgical treatment at the Affiliated Hospital of Xuzhou Medical University from January 2020 to December 2022 were simply and randomly selected and grouped into two groups according to the randomized table method:the reference group(n=30)and the observation group(n=30).In the reference group,CAPEOX chemotherapy was applied after surgery,and in the observation group,SOX chemotherapy was applied after surgery,and the clinical efficacy,serum tumor marker level,and the occurrence of adverse reactions of the two groups were statistically compared.Results Compared with the reference group,the total clinical efficacy rate(93.33%)of the observation group was higher,and the difference was statistically significant(χ^(2)=4.320,P<0.05).Before treatment,there was no statistically significant difference in levels of carbohydrate cancer antigen 199(CA199),carbohydrate cancer antigen 242(CA242),carbohydrate cancer antigen 724(CA724)and carcinoembryonic antigen(CEA)in the two groups(P>0.05).After treatment,the levels of CA199,CA242,CA724,and CEA in the observation group were lower than those in the reference group,with statistical differences between the groups,and the difference was statistically significant(P<0.05).In terms of the incidence of adverse reactions,there was no statistically significant difference between the two groups(P>0.05).Conclusion The clinical effect of SOX chemotherapy regimen in the treatment of stageⅡ-Ⅲgastric cancer is more accurate,and it can further reduce the level of serum tumor markers and does not significantly increase the adverse reactions.
作者
徐海洋
XU Haiyang(Department of Oncology,Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu Province,221000 China)
出处
《中外医疗》
2023年第22期128-131,共4页
China & Foreign Medical Treatment
关键词
胃癌
卡培他滨
奥沙利铂甘露醇
替吉奥
临床疗效
不良反应
Gastric cancer
Capecitabine
Oxaliplatin mannitol
Tegafur
Clinical efficacy
Adverse reactions
作者简介
徐海洋(1980-),男,本科,副主任医师,研究方向为肿瘤内科方面。
